ÂÜÀòÂÒÂ×

Mark has served as a member of the board of directors since September 2018. He is a co-founder of publicly held Intercept Pharmaceuticals Inc., where he also has served as president and CEO, and as a member of the board of since the company’s inception in 2002. He has more than 20 years of experience in life sciences company management, venture capital, and strategic consulting. Prior to Intercept, Mark was a venture partner at Apple Tree Partners, an early-stage life sciences venture capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, also a venture capital firm. He currently serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Mark earned a Doctor of Medicine from McMaster University in Hamilton, Canada, a Master of Arts degree in international affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy, and Washington, D.C., and a bachelor’s degree from McGill University in Montreal, Canada.